Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27316941 | 1.00 | LMNA (0.57) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| SCHEMBL9108031 | 1.00 | LMNA (0.57) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| SCHEMBL31544298 | 0.98 | LMNA (0.55) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| SCHEMBL27480900 | 0.98 | LMNA (0.55) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| SCHEMBL27469609 | 0.98 | LMNA (0.55) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| SCHEMBL30469495 | 0.93 | LMNA (0.48) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| SCHEMBL27604552 | 0.93 | LMNA (0.48) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| SCHEMBL27521459 | 0.91 | LMNA (0.47) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| Piperazine SCHEMBL27952189 | 0.89 | LMNA (0.47) | LMNAPDE4AL3MBTL1TDP1USP2 | |
| SCHEMBL9651828 | 0.84 | PDE4A (0.58) | LMNAPDE4AL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1947796-B | Chemical modified adefovir and tynofovir | ZHENGDA TIANQING PHARMACEUTICAL CO LTD JIANGSU PROV | 2010-11-24 | — | — | CN | claimed |
| CN-100409841-C | Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration | PHARMASCIENCE LAB (FR) | 2008-08-13 | — | — | CN | claimed |
| US-20040067910-A1 | Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration | LABORATOIRES EXPANSCIENCE (FR) | 2004-04-08 | — | — | US | claimed |
| CN-1486179-A | Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration | 实验室发展科学公司 | 2004-03-31 | — | — | CN | claimed |
| EP-1343486-A1 | PHARMACEUTICAL OR COSMETIC COMPOSITION AND USE OF A PKC INHIBITOR WITH AN MMP INHIBITOR FOR INHIBITING LANGERHANS' CELL MIGRATION | Laboratoires Expanscience (FR) | 2003-09-17 | — | — | EP | claimed |
| WO-2002040004-A1 | PHARMACEUTICAL OR COSMETIC COMPOSITION AND USE OF A PKC INHIBITOR WITH AN MMP INHIBITOR FOR INHIBITING LANGERHANS' CELL MIGRATION | LABORATOIRES EXPANSCIENCE (FR) | 2002-05-23 | — | — | WO | claimed |
| JP-1279837-A | — | — | None | — | — | JP | disclosed |
| CN-102884077-B | Conjugated FVIII variants | 诺沃—诺迪斯克有限公司 | 2016-06-08 | — | — | CN | disclosed |
| US-9018166-B2 | Conjugated FVIII variants | NOVO NORDISK A/S (DK) | 2015-04-28 | — | — | US | disclosed |
| EP-2536755-A1 | CONJUGATED FVIII VARIANTS | Novo Nordisk A/S (DK) | 2012-12-26 | — | — | EP | disclosed |
| US-20120322738-A1 | CONJUGATED FVIII VARIANTS | NOVO NORDISK A/S (DK) | 2012-12-20 | — | — | US | disclosed |
| WO-2011101267-A1 | CONJUGATED FVIII VARIANTS | NOVO NORDISK A/S (DK) | 2011-08-25 | — | — | WO | disclosed |
| US-20110009333-A1 | PHARMACEUTICAL OR COSMETIC COMPOSITION AND USE OF A PKC INHIBITOR WITH AN MMP INHIBITOR FOR INHIBITING LANGERHANS' CELL MIGRATION | LABORATORIES EXPANSCIENCE | 2011-01-13 | — | — | US | disclosed |
| US-4937232-A | Inhibition of protein kinase C by long-chain bases | DUKE UNIVERSITY (US) | 1990-06-26 | — | — | US | disclosed |
| EP-0372062-A1 | INHIBITION OF LIPOGENESIS | CITY OF HOPE (US) | 1990-06-13 | — | — | EP | disclosed |
| WO-1989011295-A1 | INHIBITION OF LIPOGENESIS | DEMEYTS PIERRE (US) | 1989-11-30 | — | — | WO | disclosed |
| JP-H01279837-A | LIPOGENESIS INHIBITORY/THERAPEUTIC AGENT | CITY OF HOPE | 1989-11-10 | — | — | JP | disclosed |
| US-4816450-A | ANTIINFLAMMATORY AGENTS, AMINE COMPOUNDS | DUKE UNIVERSITY (US) | 1989-03-28 | — | — | US | disclosed |
| EP-0282564-A1 | INHIBITION OF PROTEIN KINASE C BY LONG-CHAIN BASES | DUKE UNIVERSITY (US) | 1988-09-21 | — | — | EP | disclosed |
| WO-1988001869-A1 | INHIBITION OF PROTEIN KINASE C BY LONG-CHAIN BASES | DUKE UNIVERSITY (US) | 1988-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067910-A1 | Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration | MMP1, MMP2, MMP13 | LMNA 2272/4885PDE4A 576/4885L3MBTL1 4653/4885 |
| US-20120322738-A1 | CONJUGATED FVIII VARIANTS | F8, F13B, F5 | LMNA 1905/4885PDE4A 972/4885L3MBTL1 3166/4885 |
| US-20110009333-A1 | PHARMACEUTICAL OR COSMETIC COMPOSITION AND USE OF A PKC INHIBITOR WITH AN MMP INHIBITOR FOR INHIBITING LANGERHANS' CELL MIGRATION | MMP1, MMP13, MMP2 | LMNA 1814/4885PDE4A 375/4885L3MBTL1 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.